Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14728183 | 0.93 | KDM4E (0.42) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL14728150 | 0.93 | KDM4E (0.44) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL14728186 | 0.91 | F2 (0.35) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL19342630 | 0.91 | KDM4E (0.42) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL14728171 | 0.91 | KDM4E (0.46) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL14728155 | 0.90 | L3MBTL1 (0.39) | KDM4EATML3MBTL1 | |
| SCHEMBL14728181 | 0.90 | F2 (0.36) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL12242941 | 0.90 | KDM4E (0.47) | KDM4EATML3MBTL1F2F10 | |
| SCHEMBL10087130 | 0.87 | KDM4E (0.50) | KDM4EATML3MBTL1PER2CRY1 | |
| SCHEMBL29371762 | 0.87 | KDM4E (0.50) | KDM4EATML3MBTL1PER2CRY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9017829-B2 | Phenanthrocarbazole compound, and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2015-04-28 | — | — | US | disclosed |
| US-9017829-B2 | Phenanthrocarbazole compound, and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2015-04-28 | — | — | US | disclosed |
| US-20130048975-A1 | PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130048975-A1 | PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048975-A1 | PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | PPOX, ORC3, CACNA2D3 | KDM4E 1626/4885ATM 4087/4885L3MBTL1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.